Ameriprise
ANRO icon

Ameriprise’s Alto Neuroscience ANRO Stock Holding History

Ameriprise’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.04M Buy
190,996
+177,672
+1,333% +$4.11M ﹤0.01% 2545
2026
Q1 		$300K Sell
13,324
-163
-1% -$3.02K ﹤0.01% 3763
2025
Q4 		$240K Hold
13,487
– – ﹤0.01% 3873
2025
Q3 		$54.2K Sell
13,487
-95
-0.7% -$315 ﹤0.01% 4016
2025
Q2 		$29.9K Sell
13,582
-1,687
-11% -$4.01K ﹤0.01% 3934
2025
Q1 		$33K Sell
15,269
-6,746
-31% -$24.1K ﹤0.01% 3960
2024
Q4 		$93.1K Buy
22,015
+1,359
+7% +$8.48K ﹤0.01% 3960
2024
Q3 		$236K Buy
+20,656
New +$253K ﹤0.01% 3710

Other funds holding ANRO

AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SSC
Spruce Street Capital New York $510M AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Ameriprise's ANRO Position: Q2 2026 in Review

Ameriprise increased its Alto Neuroscience (ANRO) stake by 1,333% in Q2 2026, buying an estimated $4.11M and bringing the position to 190,996 shares worth $5.04M. The position accounts for ﹤0.01% of the portfolio, ranked #2545.

Ameriprise first reported a position in ANRO in Q3 2024 and has held it in 8 quarters since. 114 funds tracked by Wall St. Rank hold ANRO as of Q2 2026.

  • Ameriprise held 190,996 shares of Alto Neuroscience worth $5.04M as of Q2 2026.
  • Ameriprise bought 177,672 Alto Neuroscience shares in Q2 2026, an estimated $4.11M.
  • Alto Neuroscience made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #2545 holding.
  • Ameriprise first reported a position in Alto Neuroscience in Q3 2024 and has held it in 8 quarters since.
  • 114 funds tracked by Wall St. Rank held Alto Neuroscience as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.